BioNTech vs CureVac Which Should You Buy?

BioNTech and CureVac are two leading biotechnology companies developing cutting-edge mRNA-based vaccines and therapeutics. Both companies have garnered significant attention and investor interest due to their potential to revolutionize the field of medicine. While BioNTech has gained early success with its COVID-19 vaccine in partnership with Pfizer, CureVac is also making strides in the development of mRNA vaccines. Investors are closely watching the competition between these two companies as they strive to innovate and shape the future of healthcare.

BioNTech or CureVac?

When comparing BioNTech and CureVac, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between BioNTech and CureVac.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. BioNTech has a dividend yield of -%, while CureVac has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. BioNTech reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, CureVac reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with BioNTech P/E ratio at -47.70 and CureVac's P/E ratio at -2.12. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. BioNTech P/B ratio is 1.27 while CureVac's P/B ratio is 1.56.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, BioNTech has seen a 5-year revenue growth of 27.23%, while CureVac's is 2.26%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with BioNTech's ROE at -2.57% and CureVac's ROE at -56.93%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $107.54 for BioNTech and $2.73 for CureVac. Over the past year, BioNTech's prices ranged from $76.53 to $131.49, with a yearly change of 71.81%. CureVac's prices fluctuated between $2.21 and $6.30, with a yearly change of 184.42%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.